Xintela announces that the European Patent Office (EPO) has issued a preliminary approval ("Intention to grant") for the company's patent application related to antibody treatment of Glioblastoma and other tumors of the brain using the company's target molecule integrin α10β1.
Xintela's patent application (publication number EP3258964) covers the use of integrin α10β1 antibodies for treatment and diagnosis of tumors of the central nervous system (CNS). The present intention to grant is followed by an administrative process leading to the grant of the patent. The patent, which broadens and extends Xintela's fundamental protection in this field, will be valid until 2036.
“We are very pleased with this intention to grant communication which constitutes a validation of the strength and breadth of the company’s oncology project, and adds significant value to our oncology business,” says Xintela's CEO Evy Lundgren-Åkerlund.
Xintela has previously reported that the company's targeting ADC (Antibody-Drug Conjugate) antibodies have demonstrated killing effects on glioblastoma cells both in cell studies and in an animal model. The results have been published in the journal Cancers (2019, Vol. 11, pg 587). Additionally, in December 2019, Xintela announced that the company's function-blocking antibodies have demonstrated an inhibitory effect on glioblastoma tumors in a preclinical study. The current patent application also protects the target molecule integrin α10β1 and thereto targeting antibodies for treatment of other cancers of the CNS.